Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.